Could someone provide examples that would support a separately identifiable office visit when a patient presents for a routine Belatacept infusion? The scenario is patients are receiving monthly routine maintenance Belatacept infusions as a part of post transplant treatment and the providers state that they follow the patients for multiple conditions and only see the patient every 2 - 3 months on the same day as an infusion. There are times when the patients conditions are noted as stable w/ no issues and in this instance there was a denial of the E/M stating that it is a part of the infusion administration service. Please site any sources available.
Post here your questions regarding auditing ,coding, documentation, and compliance. Also, join in on the conversation- help your fellow auditors and compliance professionals in the industry.
1 post • Page 1 of 1